An immune-modulating 28-amino-acid peptide, marketed as Zadaxin in a number of countries. It is among the more clinically studied immune peptides, though it is not FDA-approved in the United States.
Mechanism under study
Thymosin alpha-1 is proposed to promote maturation and function of T cells and dendritic cells and to modulate Toll-like-receptor signaling, broadly enhancing adaptive immune responses.
Research-reported dosing
Approved in a number of countries (as Zadaxin) — commonly 1.6 mg subcutaneously, often twice weekly, for hepatitis and as an immune adjuvant. Not FDA-approved in the United States.
10 mg vial + 2 mL bacteriostatic water = 5000 mcg/mL (5 mg/mL). (The approved Zadaxin presentation is a 1.6 mg single-dose vial.)
A 1.6 mg dose ≈ 32 units (50 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Thymosin Alpha-1 FAQ
What is Thymosin Alpha-1?
An immune-modulating 28-amino-acid peptide, marketed as Zadaxin in a number of countries. It is among the more clinically studied immune peptides, though it is not FDA-approved in the United States.
What is the half-life of Thymosin Alpha-1?
Reported roughly 2 hours in circulation.
What is the research-reported dosing for Thymosin Alpha-1?
Approved in a number of countries (as Zadaxin) — commonly 1.6 mg subcutaneously, often twice weekly, for hepatitis and as an immune adjuvant. Not FDA-approved in the United States.
How is Thymosin Alpha-1 reconstituted?
10 mg vial + 2 mL bacteriostatic water = 5000 mcg/mL (5 mg/mL). (The approved Zadaxin presentation is a 1.6 mg single-dose vial.)
Is Thymosin Alpha-1 FDA-approved?
Thymosin Alpha-1 has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
LL-37
Cathelicidin-derived antimicrobial peptide
The only human cathelicidin antimicrobial peptide, studied for direct antimicrobial activity as well as roles in inflammation and wound healing. Human therapeutic use is investigational.
KPV
Alpha-MSH-derived tripeptide
A tripeptide fragment (Lys-Pro-Val) derived from the C-terminus of alpha-MSH, studied for anti-inflammatory effects, particularly in models of gut inflammation.
Larazotide
Synthetic octapeptide (tight-junction regulator)
An orally administered octapeptide studied as a 'tight-junction regulator' for reducing intestinal permeability, most notably in celiac-disease research.